Early-phase momentum is shifting — and the regions gaining ground may surprise you.
first-in-human · clinical trial · clinical research · regulatory · ANVISA · medical device
> Early-phase momentum is shifting — and the regions gaining ground may surprise you. From feasibility precision to regulatory refinement and cross-border expansion, this edition captures the forces reshaping Medtech and Biopharma execution.
In early-phase clinical development, feasibility is not a checkbox — it’s the strategic backbone of a successful study. Sponsors entering Latin America are discovering that robust, country-level feasibility assessments can dramatically reduce startup delays and optimize trial execution.
From first-in-human device studies to proof-of-concept programs in Biopharma, the region offers meaningful advantages — but only when operational planning is grounded in local regulatory realities, site capabilities, and patient access dynamics.
Key Considerations for Strong Feasibility Planning:
Conduct in-depth country and site-level regulatory assessments Evaluate investigator experience in early-phase and complex protocols Assess patient population access and enrollment projections realistically Align study design with local ethics and regulatory expectations Partner with teams experienced in navigating Latin American frameworks
Brazil continues to strengthen regulatory transparency for medical device sponsors. Recent clarification regarding the unification of petition subject codes tied to CBPF (Brazilian Good Manufacturing Practices Certification) reinforces structural consistency under RDC 497/2021.
For companies preparing to conduct clinical trials or enter the Brazilian market, understanding how petition classifications interact with manufacturing certifications is essential for avoiding procedural missteps and ensuring smooth regulatory submissions.
Does your company need accelerated first-in-human clinical trial results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Leverage 20+ years of expertise across Medtech, Biopharma, and Radiopharma first-in-human trials Navigate Latin America’s regulatory environment and access high-quality research sites Get tailored support for study design, approvals, site selection, and patient recruitment
Bring your innovations to market faster with Latin America’s first-in-human trial experts.
Schedule your first-in-human trial consultation at bioaccessla.com
Global Medtech expansion into Latin America continues to accelerate, with advanced digital health solutions gaining traction across key markets. Strategic distribution partnerships in countries like Peru are opening the door for cutting-edge cardiac diagnostics and AI-driven monitoring technologies to reach broader patient populations.
As wearable and remote cardiac monitoring solutions evolve, Latin America is emerging not only as a commercial growth region but also as a strategic environment for clinical validation and real-world data generation.
Key Highlights:
Expansion of advanced cardiac diagnostics into Peru Strengthening of regional distribution infrastructure Growing demand for AI-enabled remote monitoring technologies Increasing alignment between digital health innovation and LATAM market growth
Mexico is redefining its industrial identity. Long recognized for automotive manufacturing, the country is now positioning Medtech and pharmaceutical production as strategic growth engines, transforming into an innovation-driven healthcare hub.
Strengthened by nearshoring trends, skilled technical talent, and proximity to the U.S. market, Mexico is attracting global healthcare manufacturers looking to optimize supply chains and expand regional capabilities.
Why It Matters: As Mexico strengthens its Medtech and Biopharma industrial base, the supporting ecosystem for regulatory compliance, quality systems, and clinical research continues to mature — making the country an increasingly strategic destination not only for manufacturing, but also for early-phase clinical development in Latin America.
As medical device innovation accelerates, regulatory complexity continues to grow across global markets. Country-specific approval pathways, evolving ISO standards, and increasingly detailed clinical trial documentation requirements are reshaping how early-stage development strategies are structured.
Regulatory planning can no longer be an afterthought. Alignment between manufacturing certifications, quality systems, and clinical documentation is becoming essential well before trial initiation — particularly as authorities demand greater transparency and harmonization across jurisdictions.
Visionary leadership continues to shape the evolution of early-phase clinical research across emerging markets. As global sponsors seek faster pathways from concept to clinical validation, experienced operational leadership is becoming a critical differentiator in navigating regulatory landscapes, site activation, and study execution.
Strategic direction grounded in regional expertise is helping transform how first-in-human, early feasibility, and proof-of-concept studies are deployed across Latin America and other growth regions.
Key Themes:
Operational efficiency in early-phase trial execution Cross-border collaboration and regulatory navigation Building high-performing research site networks Aligning innovation with regional healthcare infrastructure
Why It Matters: Strong leadership in clinical research organizations directly impacts startup speed, regulatory alignment, and execution quality. As early-phase programs expand across Latin America, experienced guidance is essential to translate innovation into reliable, high-quality clinical data.
Feasibility-first planning is reshaping early-phase trial success in Latin America Brazil's ANVISA continues refining regulatory codes for medical device sponsors Digital cardiology and AI-driven monitoring are expanding into South America Mexico is positioning itself as a Medtech and Biopharma industrial powerhouse Global regulatory complexity demands early alignment of clinical and manufacturing documentation Experienced leadership is critical for accelerating first-in-human trials across emerging markets
This edition of Global Trial Accelerators™ by bioaccess® covers clinical trial feasibility best practices in Latin America, ANVISA regulatory updates for medical device sponsors in Brazil, digital cardiology expansion into South America, Mexico's emergence as a Medtech and Biopharma manufacturing hub, global medical device regulatory trends for 2026, and leadership strategies driving clinical research acceleration across emerging markets.
← All Global Trial Accelerators editions · Contact bioaccess®